MX2009006401A - Indazole derivatives as kinase inhibitors for the treatment of cancer. - Google Patents
Indazole derivatives as kinase inhibitors for the treatment of cancer.Info
- Publication number
- MX2009006401A MX2009006401A MX2009006401A MX2009006401A MX2009006401A MX 2009006401 A MX2009006401 A MX 2009006401A MX 2009006401 A MX2009006401 A MX 2009006401A MX 2009006401 A MX2009006401 A MX 2009006401A MX 2009006401 A MX2009006401 A MX 2009006401A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- kinase inhibitors
- indazole derivatives
- formula
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Substituted indazole derivativesof formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer. formula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06126701 | 2006-12-20 | ||
PCT/EP2007/063998 WO2008074749A1 (en) | 2006-12-20 | 2007-12-14 | Indazole derivatives as kinase inhibitors for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006401A true MX2009006401A (en) | 2009-06-23 |
Family
ID=39245139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006401A MX2009006401A (en) | 2006-12-20 | 2007-12-14 | Indazole derivatives as kinase inhibitors for the treatment of cancer. |
Country Status (15)
Country | Link |
---|---|
US (1) | US8114865B2 (en) |
EP (1) | EP2120932B1 (en) |
JP (1) | JP5302896B2 (en) |
CN (1) | CN101594862B (en) |
AU (1) | AU2007336335B8 (en) |
BR (1) | BRPI0720589A2 (en) |
CA (1) | CA2673095C (en) |
DK (1) | DK2120932T3 (en) |
EA (1) | EA017852B1 (en) |
ES (1) | ES2509820T3 (en) |
MX (1) | MX2009006401A (en) |
PL (1) | PL2120932T3 (en) |
PT (1) | PT2120932E (en) |
SI (1) | SI2120932T1 (en) |
WO (1) | WO2008074749A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
US8183381B2 (en) * | 2007-07-19 | 2012-05-22 | Metabolex Inc. | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
CA2693901C (en) | 2007-07-20 | 2015-12-29 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
ES2630026T3 (en) * | 2008-12-18 | 2017-08-17 | Nerviano Medical Sciences S.R.L. | Active substituted indazole derivatives as kinase inhibitors |
AR078411A1 (en) | 2009-05-07 | 2011-11-09 | Lilly Co Eli | IMIDAZOLIL VINYL COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
US8410127B2 (en) | 2009-10-01 | 2013-04-02 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
KR20130006664A (en) * | 2010-03-16 | 2013-01-17 | 다나-파버 캔서 인스티튜트 인크. | Indazole compounds and their uses |
WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
FR2970967B1 (en) | 2011-01-27 | 2013-02-15 | Pf Medicament | AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS A MEDICINAL PRODUCT |
PL2707359T3 (en) * | 2011-05-12 | 2017-05-31 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
WO2013038390A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | N-substituted heterocyclyl carboxamides |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
RU2632206C2 (en) * | 2012-04-05 | 2017-10-03 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | New alkylating agents |
NZ716487A (en) * | 2012-05-23 | 2017-01-27 | Nerviano Medical Sciences Srl | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
KR101936851B1 (en) * | 2012-07-16 | 2019-01-11 | 한국과학기술연구원 | Pyrazolopyridine or indazole derivatives as protein kinase inhibitors |
EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
US10208043B2 (en) | 2012-08-22 | 2019-02-19 | Cornell University | Methods for inhibiting fascin |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
WO2015110467A1 (en) * | 2014-01-23 | 2015-07-30 | Nerviano Medical Sciences S.R.L. | Process for the preparation of substituted n-(5-benzenesulfonyl-1h-indazol-3-yl)-benzamides |
US10231965B2 (en) * | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
DK3107902T3 (en) * | 2014-02-20 | 2021-05-03 | Cornell Univ Cornell Center For Technology Enterprise & Commercialization Cctec | CONNECTIONS AND METHODS OF INHIBITING FASCIN |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
JP6744309B2 (en) * | 2014-12-02 | 2020-08-19 | イグニタ,インコーポレイテッド | Combination for the treatment of neuroblastoma |
WO2016096709A1 (en) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
CA2972239A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
CN104530045A (en) * | 2015-01-14 | 2015-04-22 | 中国药科大学 | Pyrazolo[4,3-c]tetrahydropyridine c-Met kinase inhibitors as well as preparation method and application thereof |
US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
EP3273966B1 (en) | 2015-03-27 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
WO2017106492A1 (en) | 2015-12-18 | 2017-06-22 | Ignyta, Inc. | Combinations for the treatment of cancer |
US10292983B2 (en) | 2016-08-03 | 2019-05-21 | Cymabay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
BR112020000793A2 (en) | 2017-07-19 | 2020-07-14 | Ignyta, Inc. | pharmaceutical compositions and dosage forms |
CA3072493A1 (en) | 2017-08-16 | 2019-02-21 | Vanderbilt University | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
JP7311498B2 (en) | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | Pharmaceutical compositions and dosage forms |
CN110452176A (en) * | 2018-05-07 | 2019-11-15 | 四川大学 | Indazole analog derivative and its preparation method and application |
EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2004359A3 (en) * | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazole derivatives exhibiting kinase inhibitor activity, process of their preparation and pharmaceutical compositions in which the derivatives are comprised |
FR2836915B1 (en) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES THEREOF AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
WO2004078116A2 (en) * | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
FR2871158A1 (en) * | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |
EP1853590A1 (en) * | 2005-03-03 | 2007-11-14 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
AR071780A1 (en) * | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | BICYCLE CARBONILAMINO-PIRAZOLES CARBAMILILE DERIVATIVES AS PROFARMACOS |
-
2007
- 2007-12-14 PL PL07857632T patent/PL2120932T3/en unknown
- 2007-12-14 AU AU2007336335A patent/AU2007336335B8/en not_active Ceased
- 2007-12-14 CA CA2673095A patent/CA2673095C/en not_active Expired - Fee Related
- 2007-12-14 DK DK07857632.9T patent/DK2120932T3/en active
- 2007-12-14 ES ES07857632.9T patent/ES2509820T3/en active Active
- 2007-12-14 BR BRPI0720589-9A patent/BRPI0720589A2/en active Search and Examination
- 2007-12-14 MX MX2009006401A patent/MX2009006401A/en active IP Right Grant
- 2007-12-14 SI SI200731506T patent/SI2120932T1/en unknown
- 2007-12-14 WO PCT/EP2007/063998 patent/WO2008074749A1/en active Application Filing
- 2007-12-14 PT PT78576329T patent/PT2120932E/en unknown
- 2007-12-14 CN CN200780049818.0A patent/CN101594862B/en active Active
- 2007-12-14 JP JP2009542015A patent/JP5302896B2/en active Active
- 2007-12-14 US US12/520,387 patent/US8114865B2/en active Active
- 2007-12-14 EP EP07857632.9A patent/EP2120932B1/en active Active
- 2007-12-14 EA EA200970595A patent/EA017852B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN101594862A (en) | 2009-12-02 |
EA200970595A1 (en) | 2010-02-26 |
PL2120932T3 (en) | 2015-02-27 |
CA2673095C (en) | 2016-03-15 |
WO2008074749A1 (en) | 2008-06-26 |
AU2007336335A8 (en) | 2014-07-24 |
AU2007336335B2 (en) | 2013-05-30 |
CA2673095A1 (en) | 2008-06-26 |
BRPI0720589A2 (en) | 2014-02-25 |
ES2509820T3 (en) | 2014-10-20 |
SI2120932T1 (en) | 2014-09-30 |
CN101594862B (en) | 2015-11-25 |
US8114865B2 (en) | 2012-02-14 |
US20100197665A1 (en) | 2010-08-05 |
EP2120932B1 (en) | 2014-07-09 |
AU2007336335A1 (en) | 2008-06-26 |
EA017852B1 (en) | 2013-03-29 |
EP2120932A1 (en) | 2009-11-25 |
AU2007336335B8 (en) | 2014-07-24 |
JP5302896B2 (en) | 2013-10-02 |
PT2120932E (en) | 2014-10-10 |
JP2010530840A (en) | 2010-09-16 |
AU2007336335A2 (en) | 2009-08-06 |
WO2008074749A9 (en) | 2009-05-07 |
DK2120932T3 (en) | 2014-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006401A (en) | Indazole derivatives as kinase inhibitors for the treatment of cancer. | |
UA99141C2 (en) | Substituted indazole derivatives active as kinase inhibitors | |
HK1136292A1 (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
PL2324008T3 (en) | 3,4-diarylpyrazoles as protein kinase inhibitors | |
WO2009071480A3 (en) | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors | |
ATE514699T1 (en) | SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVES AS KINASE INHIBITORS | |
MY142019A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
MXPA06000302A (en) | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. | |
MX2008012422A (en) | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors. | |
MY143206A (en) | 1h-thieno 2,3-c pyrazole derivatives useful as kinase i inhibitors | |
ATE411022T1 (en) | PYRIDYLPYRROLE DERIVATIVES AS EFFECTIVE KINASE INHIBITORS | |
MX2009010059A (en) | Quinoline derivatives for the treatment of inflammatory diseases. | |
WO2009007749A3 (en) | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | |
MX2008013212A (en) | 4-anilinoquinoline-3-carboxamides as csf-1r kinase inhibitors. | |
MY139072A (en) | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
BRPI0413438A (en) | active pyrimidylpyrrole derivatives as kinase inhibitors | |
UA102219C2 (en) | Substotuted pyrazolo-quinazoline derivatives, process for the preparation and use thereof as kinase inhibitors | |
TW200502236A (en) | Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents | |
CU20060152A7 (en) | DERIVATIVES 1H-TIENO [2,3-C] PIRAZOL USEFUL AS QUINASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |